Kiran Mazumdar-Shaw: India's Biotech Startups Need Follow-On Capital

By Nathan Brooks

India's biotech startups are running short of the two things founders rarely control: follow-on capital and clear exit routes for their early investors. That's the warning from Kiran Mazumdar-Shaw, executive chairperson of Biocon and Biocon Biologics, in an interview with SME Futures.

Her diagnosis is blunt and, for practitioners, familiar. India has solved the top of the funding funnel. Seed checks and early-stage enthusiasm aren't the bottleneck anymore. What's missing is the middle and the end of the capital chain — growth-stage money that lets a promising biotech actually scale, and exit mechanisms that let early backers cash out and recycle their returns into the next cohort.

Why follow-on capital is the pinch point

Biotech doesn't scale like software. A SaaS startup can stretch a round for years on modest burn. A biotech company burns through capital in R&D, clinical validation and regulatory approvals long before it books meaningful revenue. Mazumdar-Shaw's point, as reported by SME Futures, is that Indian biotech founders who clear the early hurdles then hit a financing wall precisely when their capital needs get larger and their milestones more expensive.

For founders, that means the real planning question isn't whether you can raise a seed round. It's whether anyone will write the Series B and C checks three and four years down the road. If that money isn't there, promising platforms stall, teams disperse and intellectual property sits idle.

For investors, the calculus is equally practical. An asset you can't exit is an asset you can't fully value.

What does this change for investors?

Mazumdar-Shaw zeroes in on exits because illiquidity ripples backward through the whole chain. When early-stage investors can't see a credible path to returns — through acquisitions, secondary sales or listings — they commit less, price deals more defensively, or skip the sector entirely.

The sector's headline numbers have looked strong in recent years, with thousands of biotech startups registering across India and pandemic-era attention pulling capital toward vaccine and diagnostics players. But Mazumdar-Shaw's framing suggests the base is wider than the funding structure supporting it. Follow-on capital decides which of those startups become companies rather than experiments.

Her stance carries weight because she's speaking as both an operator and an investor-adjacent voice in the ecosystem. Biocon grew through the exact phases she's describing — scale-up capital, partnerships, eventual listings of Biologics — so her read on where the pipeline clogs comes from experience, not theory.

The so-what for the sector

If policymakers and institutional capital take her argument seriously, expect pressure for deeper domestic growth-stage funds, more structured exit windows and possibly regulatory nudges toward listings for life-science assets. If they don't, India risks a familiar pattern: strong science, strong founders, and value that matures elsewhere.

Mazumdar-Shaw's message to the ecosystem, per SME Futures, is that the hard part of building a biotech sector isn't starting companies. It's financing them all the way through.